S. 1132Senate117th Congress (2021-2023)In Committee

EPI Act

Introduced April 15, 2021

AI-Generated Summary

Updated February 8, 2026 at 1:41 AM UTC

The Ending Pricey Insulin (EPI) Act sets a $50 limit on out‑of‑pocket costs for a 30‑day supply of insulin. It applies to people with private group or individual health plans, Medicare, Medicaid, CHIP, veterans, and TRICARE enrollees, and also caps the cash price for uninsured individuals. The law requires any excess charges paid after Jan. 1, 2022 to be reimbursed to the affected patients.

Key Provisions

  • Group health plans and insurers cannot require deductibles, copayments, or coinsurance that make insulin cost more than $50 per 30‑day prescription starting in 2022.
  • Medicare, Medicaid, CHIP, Medicare Advantage, and Part D drug plans must also limit out‑of‑pocket insulin costs to $50 per 30‑day supply.
  • Veterans receiving insulin through the VA must have out‑of‑pocket costs capped at $50 per 30‑day supply.
  • TRICARE enrollees must not pay more than $50 out‑of‑pocket for a 30‑day insulin supply.
  • Uninsured individuals may not be charged more than $50 for a 30‑day supply of insulin, and any higher cash price paid after Jan. 1, 2022 must be reimbursed by the manufacturer.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

1 earlier action
SenateIntro Referral Latest Action

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

April 15, 2021

View full timeline
SenateIntro Referral

Introduced in Senate

April 15, 2021

SenateIntro Referral

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

April 15, 2021

Floor Debate

5 members

What members said about S. 1132 on the floor

3 Republicans2 Democrats
John Kennedy
Sen. John KennedyR-LA · Apr 15, 2021

Mr. President, I ask unanimous consent that the order for the quorum call be rescinded. Mr. President, I want to talk a little bit today about a subject that I have struggled with in terms of how to…

John Thune
Sen. John ThuneR-SD · Apr 15, 2021

Madam President, I ask unanimous consent that the order for the quorum call be rescinded. Madam President, I am feeling a sense of deja vu this morning. In March, Democrats used reconciliation to…

Mike Crapo
Sen. Mike CrapoR-ID · Apr 15, 2021

Mr. President, in reserving the right to object, first of all, I want to respond to Senator Kennedy. The first thing I want to say to Senator Kennedy is that I am impressed. He did this in only five…

Richard Blumenthal
Sen. Richard BlumenthalD-CT · Apr 15, 2021

Madam President, I feel very privileged to be here today to speak on behalf of Vanita Gupta, a dedicated public servant who is devoted, deeply devoted, to equal justice, civil rights, and the rule of…

Charles E. Schumer
Sen. Charles E. SchumerD-NY · Apr 15, 2021

Mr. President, I ask unanimous consent that the order for the quorum call be rescinded.

Bill Text

Latest available legislative text

Reading Mode
Latest
Introduced in SenateIssued April 15, 2021

II

117th CONGRESS

1st Session

S. 1132

IN THE SENATE OF THE UNITED STATES

April 15, 2021

Mr. Kennedy introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

A BILL

To establish a cap on out-of-pocket costs for insulin.

1.

Short title

This Act may be cited as the Ending Pricey Insulin Act or the EPI Act.

2.

Capping out-of-pockets cost of insulin

(a)

Individuals enrolled in certain health plans

Title XXVII of the Public Health Service Act (42 U.S.C. 300gg et seq.) is amended by inserting after section 2729 the following:

2729A.

Coverage of insulin drugs

Beginning with plan year 2022, a group health plan or health insurance issuer offering group or individual health insurance coverage that provides coverage for prescription insulin drugs may not impose any deductible, copayment, coinsurance, or other cost-sharing requirement with respect to such drugs that results in out-of-pocket costs to the enrollee that exceed $50 per prescription for a 30-day supply of covered prescription insulin drugs, regardless of the amount of insulin drugs needed to fill the enrollee's insulin prescriptions.

.

(b)

Individuals enrolled in other coverage

(1)

Medicare, Medicaid, and CHIP

The Secretary of Health and Human Services shall take such administrative action as is necessary to ensure that in no event shall any State plan or waiver under title XIX or XXI of the Social Security Act or prescription drug plan under part D of title XVIII of such Act or MA–PD plan under part C of such title of such Act that provides coverage for prescription insulin drugs impose any deductible, copayment, coinsurance, or other cost-sharing requirement with respect to such drugs that results in out-of-pocket costs to an individual enrolled in such coverage that exceeds $50 per prescription for a 30-day supply of covered prescription insulin drugs, regardless of the amount of insulin drugs needed to fill the enrollee's insulin prescriptions.

(2)

Veterans

The Secretary of Veterans Affairs shall take such administrative action as is necessary to ensure that prescription insulin drugs written by eligible health care providers for veterans do not impose any deductible, copayment, coinsurance, or other cost-sharing requirement with respect to such drugs that results in out-of-pocket costs to the veteran that exceeds $50 per prescription for a 30-day supply of covered prescription insulin drugs, regardless of the amount of insulin drugs needed to fill the veteran's insulin prescriptions. For purposes of the preceding sentence, the term eligible health care provider means a health care provider under section 1703(c) of title 38, United States Code, or an eligible entity or provider under section 1703A(b) of such title.

(3)

TRICARE

The Secretary of Defense shall take such administrative action as is necessary to ensure that prescription insulin drugs written by health care providers for enrollees in the TRICARE program under chapter 55 of title 10, United States Code, do not impose any deductible, copayment, coinsurance, or other cost-sharing requirement with respect to such drugs that results in out-of-pocket costs to enrollees that exceeds $50 per prescription for a 30-day supply of covered prescription insulin drugs, regardless of the amount of insulin drugs needed to fill the enrollee's insulin prescriptions.

3.

Cap on cash price for insulin for individuals without health insurance

Beginning on January 1, 2022, in the case of an individual who is not enrolled in any public or private health plan, the cash price for a 30-day supply of such individual's prescription insulin drugs, regardless of the amount of insulin drugs needed to fill the individual's insulin prescriptions, shall be not more than $50.

4.

Retroactive effect

In the event that this Act is enacted after January 1, 2022—

(1)

any out-of-pocket cost to an enrollee for insulin in plan year 2022 or a subsequent plan year that is in excess of the amount specified in section 2729A of the Public Health Service Act (as added by section 2) shall be reimbursed by the group health plan or health insurance issuer to the enrollee;

(2)

any amount paid by an uninsured individual for insulin on or after January 1, 2022, that is in excess of the amount specified in section 3 shall be reimbursed by the insulin manufacturer to the individual; and

(3)

any amount paid by an enrollee or veteran for insulin on or after January 1, 2022, that is in excess of the amount specified in paragraph (1) (2), or (3), as applicable, of section 2(b) shall be reimbursed by the Secretary of Health and Human Services, the Secretary of Veterans Affairs, or the Secretary of Defense, as applicable, to the enrollee or veteran.